LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home ...

On November 19, 2025, Anavex announced that it will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14th, 2026, at the Westin St. Francis in San Francisco, CA with ...

If you care about Alzheimer’s disease, please read studies that bad lifestyle habits can cause Alzheimer’s disease, and strawberries can be good defence against Alzheimer’s.

Scientists have uncovered a surprising mechanism by which a brain enzyme called OTULIN controls the expression of tau, the ...

An oral version of the GLP-1 drug semaglutide failed to significantly slow the disease's progression compared to a placebo.

Scientists have failed to show that weight-loss wonder drug semaglutide slows the progress of Alzheimer's disease (AD), as ...

Novo Nordisk A/S’ wild card bet that its GLP-1 receptor agonist semaglutide could be used to treat Alzheimer’s disease has ...

The studies were a significant setback for the optimistic view that semaglutide and other GLP-1 drugs could help prevent a ...

The biomarker improvements in the EVOKE studies are worth noting, observed Howard Fillit, MD, of the Alzheimer's Drug ...

Despite encouraging biomarker shifts, oral semaglutide failed to slow cognitive decline in early Alzheimer’s, leading to an early end of the trial extension.

Rutgers neuroscientist Peng Jiang and his neuroscience colleague Mengmeng Jin have made a discovery they say could reshape ...

An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression ...